Xiaohui He - Concepedia

Author

Xiaohui He

Chinese Academy of Medical Sciences & Peking Union Medical College ORCID

Also Known As

He, Xiao-Hui, He, Xiaohui, X H He, X. He, XIAOHUI HE, Xianming He, Xiao-Hui He, Xiao-hui He, Xiaohong Han, Xiaohui He

262

Publications

4.3K

Citations

H-Index

Concepts

All Affiliations

Chinese Academy of Medical Sciences & Peking Union Medical College Peking University Peking Union Medical College Hospital Sun Yat-sen University Sun Yat-sen University Cancer Center

About

Xiaohui He is an author at Chinese Academy of Medical Sciences & Peking Union Medical College specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	27	2.3K
2	Health Sciences	10	10	800
3	Natural Sciences	2	2	84
4	Engineering	1	1	48
5	Public Health	1	1	18

Xiaohui He

Publications

Citations

H-Index

Page 1

	Year	Citations
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials Wenfeng Fang, Yunpeng Yang, Yuxiang Ma, The Lancet Oncology MedicineImmunologyPathologyImmune Checkpoint InhibitorNasopharyngeal Carcinoma	2018	495
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial Yunpeng Yang, Song Qu, Jingao Li, The Lancet Oncology MedicineClinical TrialsImmune Checkpoint InhibitorCamrelizumab Versus PlaceboPharmacotherapy	2021	429
Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Nature Medicine OncologyMetronomic TherapyNasopharyngeal CancerFirst-line TreatmentCancer Treatment	2021	387
Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma Ye‐Xiong Li, Bo Yao, Jing Jin, Journal of Clinical Oncology	2005	357
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma Hai‐Qiang Mai, Qiuyan Chen, Dongping Chen, JAMA	2023	196
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309) Yunpeng Yang, Jianji Pan, Hui Wang, Cancer Cell R/m NpcImmunologyPathologyFirst-line TreatmentImmunotherapeutics	2023	191
SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol Gino Boily, Xiaohui He, Brenda Pearce, Oncogene Oncogenic AgentMedicineNormal RatesPathologyCancer Biology	2009	135
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China Yuankai Shi, Ying Han, Jianliang Yang, Chinese Journal of Cancer Research	2019	121
Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients Bo Li, Yuankai Shi, Xiaohui He, International Journal of Hematology Lymphoid NeoplasiaGastroenterologyPathologyClinicopathological CharacteristicsGastrointestinal Pathology	2008	104
Efficacy, safety, and biomarker analysis of Camrelizumab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma (CAPTAIN study) Yunpeng Yang, Ting Zhou, Xiaozhong Chen, Journal for ImmunoTherapy of Cancer	2021	88

Page 1